ARMP Stock Risk & Deep Value Analysis
Armata Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About ARMP Stock
We analyzed Armata Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ARMP through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ARMP Risk Analysis & Red Flags
What Could Go Wrong
The company's critically low cash balance of $14.1M (as of Q4 2025) and 'going concern' warning mean it needs substantial capital very soon. Failure to secure favorable financing or significant dilution of existing shareholders could devastate the stock price, even with strong clinical progress.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Critical cash position and auditor's 'going concern' warning (Q4 2025 financials, filed March 25, 2026)
- ⚠
High operating cash burn of -$26 million (TTM) relative to cash reserves
- ⚠
Significant EPS miss in Q4 2025, indicating ongoing operational losses
- ⚠
Lack of detailed insider buying activity despite positive clinical news
Upcoming Risk Events
- 📅
Failure to secure sufficient financing, leading to further significant dilution or operational delays
- 📅
Negative or inconclusive results from ongoing clinical trials
- 📅
Key competitor announcing breakthrough in antibiotic resistance
When to Reconsider
- 🚪
Failure to announce successful capital raise by Q3 2026
- 🚪
Negative or unexpected safety/efficacy data from AP-SA02 clinical trials
- 🚪
Cash balance falling below $5 million without clear path to funding
Unlock ARMP Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Armata Pharmaceuticals Inc (ARMP) Do?
Market Cap
$473.30M
Sector
Healthcare
Industry
Biotechnology
Employees
60
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
Visit Armata Pharmaceuticals Inc WebsiteInvestment Thesis
Armata Pharmaceuticals presents a high-risk, high-reward opportunity rooted in its innovative phage therapy platform, targeting the urgent global crisis of antibiotic resistance. The 10x potential is contingent on successfully completing Phase 3 trials for AP-SA02 and securing the necessary capital to commercialize a first-in-class product, establishing market leadership in a critical, underserved medical area.
Is ARMP Stock Undervalued?
Unlock the full AI analysis for ARMP
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ARMP Price Targets & Strategy
12-Month Target
$15.00
Bull Case
$25.00
Bear Case
$5.00
Valuation Basis
Based on analyst median price target of $15.00, reflecting current pipeline value and market potential prior to Phase 3 trial readouts and assuming successful financing.
Entry Strategy
Dollar-cost average at current levels ($12-$13) or on dips towards $10.00 (historical support zone, requires close monitoring for dilution news).
Exit Strategy
Take initial profits at $15.00-$18.00 if significant positive clinical data emerges or financing is secured. Set a stop loss at $9.00, especially if significant dilution or negative financial news is announced.
Portfolio Allocation
2% for aggressive risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is ARMP Financially Healthy?
Valuation
P/E Ratio
-2.88
Price/Book
-2.33
Profitability
Gross Margin
100.00%
Operating Margin
-747.02%
Net Margin
-3544.03%
Return on Equity
-120.00%
Revenue Growth
-5.22%
EPS
$-4.79
Balance Sheet
Current Ratio
1.19
Quick Ratio
1.02
Other
Beta (Volatility)
1.59
Does ARMP Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
If AP-SA02 successfully navigates Phase 3 and gains market approval, Armata's unique phage library, manufacturing expertise, and early regulatory designations could create a defensible position, making replication difficult for new entrants for 10-20 years.
Moat Erosion Risks
- •Failure of clinical trials, undermining IP value
- •Emergence of superior or more cost-effective alternative treatments for antibiotic-resistant infections
- •Manufacturing scalability challenges for phage therapies
ARMP Competitive Moat Analysis
Sign up to see competitive advantages
ARMP Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral
Institutional Sentiment
Positive, with recent analyst upgrades (HC Wainwright on Feb 23, 2026: $9.00 → $15.00, Buy; JonesTrading initiation Jan 5, 2026: Buy, $15.00).
Insider Activity (Form 4)
Pierre Kyme, a director, filed a Form 4 on March 17, 2026, though specific details on shares bought/sold or dollar value were not reported in the available intelligence.
Options Flow
Normal options activity.
Earnings Intelligence
Next Earnings
2026-05-07 (Estimated Q1 2026)
Surprise Probability
Medium
Historical Earnings Pattern
Stock price reaction to earnings tends to be highly volatile, heavily influenced by clinical trial updates, regulatory news, and financing announcements rather than revenue/EPS figures alone.
Key Metrics to Watch
Competitive Position
Top Competitor
MIRM (Mirum Pharmaceuticals, larger-cap specialty pharma, not direct phage competitor)
Market Share Trend
N/A, pre-commercialization. Aiming to establish market share in a new therapeutic area.
Valuation vs Peers
Trading at a significant discount based on traditional P/E or P/B multiples due to pre-revenue clinical stage and financial risk, but high premium implied by potential peak sales if pipeline is successful.
Competitive Advantages
- •Proprietary bacteriophage platform and manufacturing capabilities
- •Positive regulatory designations (QIDP, EOP2 alignment for AP-SA02)
- •Addresses critical unmet need for antibiotic-resistant infections
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ARMP Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings report (expected May 7, 2026)
- •Updates on AP-SA02 Phase 3 trial initiation and enrollment
Medium-Term (6-18 months)
- •Successful capital raise to address 'going concern'
- •Further clinical trial advancements for other pipeline candidates (e.g., AP-PA02 for Pseudomonas)
Long-Term (18+ months)
- •Commercialization and market launch of AP-SA02 following successful trials and FDA approval
- •Expansion of phage therapy platform into new bacterial targets and geographies
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ARMP?
- ✓
Successful announcement of a non-dilutive or minimally dilutive financing event
- ✓
Positive updates on AP-SA02 Phase 3 trial progression and data
- ✓
Expansion of pipeline candidates into new clinical stages
Bull Case Analysis
See what could go right with Premium
Competing with ARMP
See how Armata Pharmaceuticals Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Armata Pharmaceuticals Inc ARMP | $473.3M | 6.8 | -2.9 | $1.1M | -3544.0% | -5.2% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Armata Pharmaceuticals Inc Makes Money
Armata Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing novel bacteriophage-based therapeutics. These therapies are designed to precisely target and kill specific bacteria, offering a potential solution to serious bacterial infections, especially those resistant to conventional antibiotics. The company's business model is currently focused on research and development, raising capital to fund its clinical trials. If successful, Armata aims to generate revenue by bringing its approved phage therapies to market, potentially through licensing agreements with larger pharmaceutical companies or direct commercialization, selling its products to hospitals and healthcare providers.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Armata Pharmaceuticals Inc (ARMP)?
As of April 26, 2026, Armata Pharmaceuticals Inc has a DVR Score of 6.8 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Armata Pharmaceuticals Inc?
Armata Pharmaceuticals Inc's market capitalization is approximately $473.3M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Armata Pharmaceuticals Inc use?
ARMP is the ticker symbol for Armata Pharmaceuticals Inc. The company trades on the ASE.
What is the risk level for ARMP stock?
Our analysis rates Armata Pharmaceuticals Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ARMP?
Armata Pharmaceuticals Inc currently has a price-to-earnings (P/E) ratio of -2.9. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Armata Pharmaceuticals Inc's revenue growing?
Armata Pharmaceuticals Inc has reported revenue growth of -5.2%. Revenue has been declining, which warrants closer examination.
Is ARMP stock profitable?
Armata Pharmaceuticals Inc has a profit margin of -3544.0%. The company is currently unprofitable.
How often is the ARMP DVR analysis updated?
Our AI-powered analysis of Armata Pharmaceuticals Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 26, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ARMP (Armata Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.